2. Search Result
Search Result
Results for "

item/HY-17026

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

3

Screening Libraries

3

Inhibitory Antibodies

3

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-17026
    Gemcitabine
    Maximum Cited Publications
    266 Publications Verification

    LY 188011

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis p38 MAPK Infection Inflammation/Immunology Cancer
    Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer .
    Gemcitabine
  • HY-160818
    MC3138
    2 Publications Verification

    		 Sirtuin Cancer
    MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC50 values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .
    MC3138
  • HY-138253
    2′,2′-Difluorodeoxyuridine

    dFdU; 2',2'-Difluoro-2'-deoxyuridine

    		 Drug Metabolite Apoptosis Cancer
    2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells .
    2′,2′-Difluorodeoxyuridine
  • HY-P9964
    Necitumumab

    11F8; IMC-11F8; LY3012211

    		 EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-17026E
    Gemcitabine triphosphate trisodium

    dFdCTP trisodium

    		 Drug Metabolite DNA/RNA Synthesis Apoptosis Cancer
    Gemcitabine triphosphate (dFdCTP) trisodium is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate trisodium cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate trisodium shows a Ki of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate trisodium partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate trisodium disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate trisodium can be used for the research of pancreatic cancer and non-small cell lung cancer .
    Gemcitabine triphosphate trisodium
  • HY-17026R
    Gemcitabine (Standard)

    LY 188011 (Standard)

    		 Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    Gemcitabine (Standard) is the analytical standard of Gemcitabine. This product is intended for research and analytical applications. Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine (Standard)
  • HY-13561
    AZM475271

    M475271

    		 Src Apoptosis Cancer
    AZM475271 (M475271) is an orally active and selective Src kinase inhibitor. AZM475271 inhibits phosphorylation of c-Src kinase, Lck, c-yes (IC50s = 0.01, 0.03, 0.08 μM, respectively). AZM475271 induces apoptosis. AZM475271 reduces tumor cell proliferation and migration in vitro and in vivo, and reduces microvessel density (MVD). AZM475271 inhibits tumor growth and metastasis. AZM475271 sensitizes tumor cells to the cytotoxic effects of Gemcitabine (HY-17026) .
    AZM475271
  • HY-108932
    Gemcitabine monophosphate

    Gemcitabine 5′-phosphate

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate
  • HY-17026A
    Gemcitabine triphosphate

    dFdCTP

    		 Drug Metabolite DNA/RNA Synthesis Apoptosis Cancer
    Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a Ki of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .
    Gemcitabine triphosphate
  • HY-P99667
    Ipafricept
    4 Publications Verification

    OMP-54F28; FZD8-Fc

    		 Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc

    		Drug-Linker Conjugates for ADC Cancer
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .
    Gemcitabine-O-Si(di-iso)-O-Mc
  • HY-138253R
    2′,2′-Difluorodeoxyuridine (Standard)

    dFdU (Standard); 2',2'-Difluoro-2'-deoxyuridine (Standard)

    		 Drug Metabolite Reference Standards Apoptosis Cancer
    2′,2′-Difluorodeoxyuridine (Standard) is the analytical standard of 2′,2′-Difluorodeoxyuridine. This product is intended for research and analytical applications. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells.
    2′,2′-Difluorodeoxyuridine (Standard)
  • HY-138253S
    2′,2′-Difluorodeoxyuridine-13C,15N2

    dFdU-13C,15N2; 2',2'-Difluoro-2'-deoxyuridine-13C,15N2

    		 Isotope-Labeled Compounds Drug Metabolite Apoptosis Others
    2′,2′-Difluorodeoxyuridine- 13C, 15N2 (dFdU- 13C, 15N2) is a 13C- and 15N-labeled compound. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells .
    2′,2′-Difluorodeoxyuridine-13C,15N2
  • HY-171414
    MC-VC-PAB-O-Gemcitabine

    		Antibiotic Bacterial Infection
    MC-VC-PAB-O-Gemcitabine is a linker-antibiotic intermediate, which is part of the antibody-antibiotic conjugate (AAC) molecule. MC-VC-PAB-O-Gemcitabine is conjugated with the linker and the antibiotic Gemcitabine (HY-17026). MC-VC-PAB-O-Gemcitabine can be used to study the immunotherapy of bacterial infections and the development of new antibacterial drugs .
    MC-VC-PAB-O-Gemcitabine
  • HY-15883
    GNE-900

    		Checkpoint Kinase (Chk) Apoptosis Cancer
    GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 μM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. Gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .
    GNE-900
  • HY-156027
    SIRT6-IN-3

    		Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-W105318
    Pentabromophenol

    PBP

    		 TGF-beta/Smad Apoptosis Cancer
    Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .
    Pentabromophenol
  • HY-106777
    Cyclopentenylcytosine
    1 Publications Verification

    CPEC; NSC 375575

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Necroptosis Influenza Virus HSV Infection Cancer
    Cyclopentenylcytosine (CPEC), a carbocyclic nucleoside analog of cytosine, is a potent inhibitor of CTP synthetase and causes depletion of CTP and dCTP pools. Cyclopentenylcytosine shows broad-spectrum (both DNA and RNA viruses) antiviral activity. Cyclopentenyl cytosine increases Gemcitabine (HY-17026) radiosensitisation in human pancreatic cancer cells. Cyclopentenylcytosine shows effective antiviral activity in the Ad5/NZW rabbit ocular replication model and shows anti-tumor activity in various tumor xenografts model. Cyclopentenylcytosine can be used for the study of infection and cancer .
    Cyclopentenylcytosine
  • HY-139901
    Chk1-IN-6

    		Checkpoint Kinase (Chk) Cancer
    Chk1-IN-6 is a selective and orally active Chk1 inhibitor with an IC50 of 16.1 nM. Chk1-IN-6 shows antiproliferative activity of MV-4-11 cells. Chk1-IN-6 exerts effective response in the MV-4-11 xenograft mouse model. Chk1-IN-6 exhibits synergistic anticancer effect with Gemcitabine (HY-17026). Chk1-IN-6 can be used in the research of cancers such as acute myeloid leukemia and colorectal adenocarcinoma .
    Chk1-IN-6
  • HY-108932A
    Gemcitabine monophosphate disodium

    Gemcitabine 5′-phosphate disodium

    		 Apoptosis Cancer
    Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate disodium
  • HY-145525
    Linoleoyl-L-carnitine chloride

    CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester

    		 Endogenous Metabolite Others
    Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.
    Linoleoyl-L-carnitine chloride
  • HY-103367
    CHK1-IN-7

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer .
    CHK1-IN-7
  • HY-174448
    WEE1-IN-12

    		Wee1 Cancer
    WEE1-IN-12 (Compound 87) is a Wee1 kinase inhibitor with an IC50 of 2.0 nM. WEE1-IN-12 can inhibit the proliferation of HT29 cells (IC50: 1.07 μM), and when used in combination with Gemcitabine (HY-17026), the effect is better (IC50: 0.34 μM). WEE1-IN-12 can be used in the research of tumors such as colon cancer .
    WEE1-IN-12
  • HY-137555
    11-dehydro-2,3-dinor Thromboxane B2

    11-deHYdro-2,3-dinor TXB2

    		 Endogenous Metabolite Metabolic Disease
    11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.
    11-dehydro-2,3-dinor Thromboxane B2
  • HY-17026S
    Gemcitabine-13C,15N2

    LY 188011-13C,15N2

    		 Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .
    Gemcitabine-13C,15N2
  • HY-161383
    CHK1-IN-9

    		Checkpoint Kinase (Chk) Cancer
    CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .
    CHK1-IN-9
  • HY-178021
    HDAC1-IN-11

    		HDAC DNA/RNA Synthesis Apoptosis RAD51 Caspase Cancer
    HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC50 of 106.6  nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research .
    HDAC1-IN-11
  • HY-178022
    HDAC6-IN-63

    		HDAC Apoptosis Caspase RAD51 DNA/RNA Synthesis Cancer
    HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC50 of 145  nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research .
    HDAC6-IN-63
  • HY-155222
    TW9

    		Epigenetic Reader Domain HDAC Cancer
    TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .
    TW9
  • HY-W114419
    Bisphenol C

    		Estrogen Receptor/ERR mTOR Cardiovascular Disease Metabolic Disease
    Bisphenol C is an estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC50 values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .
    Bisphenol C
  • HY-154842
    S-Gem

    		Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis Cancer
    S-Gem is a TrxR-dependent prodrug of Gemcitabine (HY-17026) and selectively activated by TrxR. S-Gem shows less cytotoxicity compared to Gemcitabine .
    S-Gem
  • HY-116661
    Cannabigerovarin

    CBGV

    		 Cannabinoid Receptor Metabolic Disease
    Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.
    Cannabigerovarin
  • HY-149050
    Viral polymerase-IN-1 hydrochloride

    		Influenza Virus SARS-CoV Infection
    Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC90 values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .
    Viral polymerase-IN-1 hydrochloride
  • HY-130340
    Teicoplanin A3-1

    Teichomycin A3 factor 1; Antibiotic L 17054

    		 Antibiotic Infection
    Teicoplanin A3-1 is a degradation product of teicoplanins A2-1 to 5 (Item Nos. 20187, 20188, 20189, 20192). Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro.
    Teicoplanin A3-1
  • HY-178451
    NQO1-responsive prodrug

    		Apoptosis Cancer
    NQO1-responsive prodrug is a prodrug of Gemcitabine (dFdC) (HY-17026) with anti-cancer effect. NQO1-responsive prodrug remains stable in plasma and liver/intestinal S9 fractions, releasing dFdC in an NQO1-dependent manner. NQO1-responsive prodrug induces S-phase arrest and apoptosis. NQO1-responsive prodrug inhibits tumor growth in an A549 xenograft mouse model. NQO1-responsive prodrug can be used for breast and non-small cell lung cancer (NSCLC) research .
    NQO1-responsive prodrug
  • HY-124200
    AL 8810 isopropyl ester

    		Prostaglandin Receptor Endocrinology
    AL 8810 (Item No. 16735) is an 11β-fluoro analog of prostaglandin F2α which acts as a potent and selective antagonist at the FP receptor. AL 8810 isopropyl ester is a lipid soluble, esterified prodrug form of AL 8810 analogous to the commonly used therapeutic intraocular prostaglandin compounds such as Latanoprost (HY-B0577) and Travoprost (HY-B0584).
    AL 8810 isopropyl ester
  • HY-129303
    AP219

    		Endogenous Metabolite Metabolic Disease
    AP39 (Item No. 17100) is a compound used to increase the levels of hydrogen sulfide (H2S) within mitochondria. It consists of a mitochondria-targeting motif (triphenylphosphonium) coupled to an H2S-donating moiety (dithiolethione) by an aliphatic linker. AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.
    AP219
  • HY-159577
    Nic-15

    		PI3K mTOR Akt Cancer
    Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .
    Nic-15
  • HY-134123
    Lipoxin B4 methyl ester

    LXB4 metHYl ester

    		 Drug Intermediate Leukotriene Receptor Metabolic Disease
    Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
    Lipoxin B4 methyl ester
  • HY-108932R
    Gemcitabine monophosphate (Standard)

    Gemcitabine 5′-phosphate (Standard)

    		 Reference Standards Apoptosis Cancer
    Gemcitabine monophosphate (Standard) is the analytical standard of Gemcitabine monophosphate (HY-108932). This product is intended for research and analytical applications. Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .
    Gemcitabine monophosphate (Standard)
  • HY-114563
    LY 223592

    dFdG

    		 Drug Derivative Cancer
    LY 223592 (Compound I-a) is a Gemcitabine (HY-17026) derivative. LY 223592 has the biological activity of highly selective inhibition of lung cancer cell proliferation (IC50 = 5.6 nM in A549 cells) and low cytotoxicity to normal cells. LY 223592 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) .
    LY 223592
  • HY-185323
    Gem-C12

    		Drug Derivative Apoptosis DNA/RNA Synthesis Neurological Disease Cancer
    Gem-C12 is a prodrug of Gemcitabine (HY-17026). Gem-C12 terminates DNA chain elongation, inhibits nucleic acid synthesis and induces Apoptosis. Gem-C12 inhibits the proliferation of glioma cells. Gem-C12 and Honokiol (HY-N0003) exhibit synergistic anti-glioblastoma activity. Gem-C12 can be used in research related to glioblastoma multiforme .
    Gem-C12
  • HY-182898
    Gal-dMor-Gem

    		Apoptosis Glycosidase Inflammation/Immunology
    Gal-dMor-Gem is a selective senescent cell scavenger, Apoptosis inducer, and a prodrug of Gemcitabine (HY-17026). Gal-dMor-Gem releases Gemcitabine upon activation by Esterases and β-gal. Gal-dMor-Gem reduces SA-β-gal, preferentially induces apoptosis in senescent cells, regulates apoptosis-related proteins, accumulates in senescent tissues, and ameliorates senescence-related organ phenotypes. Gal-dMor-Gem is applicable to research on chemotherapy-induced senescence .
    Gal-dMor-Gem
  • HY-P991883
    Metuzumab

    Licartin; Metuximab; Mehuzumab

    		 Apoptosis CDK Caspase Bcl-2 Family Cancer
    Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].
    Metuzumab
  • HY-176957
    PKMYT1-IN-11

    		Wee1 Cancer
    PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC50 of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer .
    PKMYT1-IN-11
  • HY-RS17026
    Bach1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Bach1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bach1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bach1 Mouse Pre-designed siRNA Set A
    Bach1 Mouse Pre-designed siRNA Set A
  • HY-N17026
    Erythrinin H

    		Drug Derivative Others
    Erythrinin H is a natural flavonoid.
    Erythrinin H

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: